Institut Pasteur, Departement of Parasitology and Mycology, Paris, France.
Trends Parasitol. 2011 Feb;27(2):82-90. doi: 10.1016/j.pt.2010.09.004. Epub 2010 Oct 26.
Artemisinin combination therapy (ACT) paves the way for new opportunities to eliminate malaria in the tropics. However, the huge increase of ACT consumption raises major concerns about their availability over the next few years. At the same time a decrease in their efficacy has already been reported. Alongside the deployment of multifocal control programs, the process ranging from artemisia crop production to accreditation of new ACT combinations urgently needs to be strengthened to supply sufficient quantities of high-quality drugs. New suppliers will have the opportunity to enter this market to develop new formulations, and bioequivalence studies are required to validate these new formulations. It is thus crucial for national malaria control teams to be able to better scrutinize the dossier of these new formulations.
青蒿素联合疗法（ACT）为消除热带地区疟疾开辟了新的机会。然而，ACT 消耗量的大幅增加引起了人们对未来几年供应情况的重大关注。与此同时，其疗效已经有所下降。除了部署多焦点控制方案外，从青蒿素作物生产到新的 ACT 组合认证的过程也急需加强，以提供足够数量的高质量药物。新的供应商将有机会进入这个市场开发新的配方，并且需要进行生物等效性研究来验证这些新的配方。因此，国家疟疾控制团队能够更好地审查这些新配方的档案至关重要。
